Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 294
Tipo Título / Nombre Autor(es) Año
Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, ????rst-in-class, oral CELMoDTM agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma Vassilakopoulos T, Muñoz J, Huang H..., Bergua Burgues JM 2025
Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis Jang JH, Barrentxea Lekue C, Bergua Burgues JM 2025
Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial Torrent A, Morgades M Barrera S..., Bergua Burgues JM 2025
Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy Paiva B, Burgos L, González C..., Bergua Burgues JM 2025
Impact of molecular profile and variant allele frequency in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group Colmenares R, Barragán E, Rodríguez Veiga R..., Bergua Burgues JM 2025
Combinación del riesgo genético basal y el aclaramiento de la enfermedad residual para asignar el tratamiento post-remisión en los pacientes adultos con leucemia aguda linfoblástica (LAL) sin cromosoma filadelfia (PH-). Resultados finales del protocolo P LAL19 Ribera Santasusana J, Torrent Catarineu A, Morgades De La Fe M, Barrena Delfa S..., Bergua Burgués J 2025
Guía asistencial del Paciente Anciano-Paciente Unfit (Guía PAPU-70+) Montesinos P, Barragán E, Lloret P..., Bergua J, [C. científico y redacción] 2025
A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study Rodríguez-Veiga R, Gil C, Sobas M, Torres-Miñana L..., Bergua J 2025
Recomendaciones PETHEMA 2025 para el tratamiento de la leucemia mieloblástica aguda en pacientes ancianos (70+) y/o no no candidatos a quimioterapia intensiva (unfit). Guía asistencial Paciente Anciano Paciente Unfit (Guía PAPU-70+) Algarra L, Botella C, Vives S..., Bergua J 2025
Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival Valhondo I, Pera A, Hassouneh F..., Bergua JM, Arcos MJ, Casas-Avilés I, Sánchez-García J, Serrano J, Durán E, Alonso C, Solana R, Tarazona R 2025